Time for new pharmaceutical-innovation models
The pharmaceutical industry is one of the most profitable on earth, expected to be worth $1.4 trillion by the end of 2020. Last year,...
High medicines prices in Europe – do not Brexit the people
The issues of high priced medicines and problems with access to medicines have for many years been themes belonging to the realm of global...
ML&P’s Comments to the Intergovernmental Negotiating Body (INB) on the Zero Draft of the...
These remarks were delivered on the occasion of the fourth meeting of the Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement...
Human Rights Watch: All governments should endorse the WHO C-TAP Solidarity Call to Action
As the race towards a Covid-19 vaccine continues – with 11 leading candidates in phase 3 clinical trials, 14 more in phase 2 and...
Remdesivir developed country price announced
On 29, June 2020 Gilead announced its global price for developed countries for remdesivir, a medicine that has shown some effect in the treatment...
Faced with unreasonable medicines prices, the Netherlands introduces pharmacy exemption in patent law.
On 1 February 2019, article 53(3), second sentence of the Dutch Patent Act 1995 came into force introducing a patent exemption for the preparation...
Gilead’s sofosbuvir patent in India – options for global access to new hepatitis C...
Earlier this month the US pharmaceutical company Gilead obtained a patent in India for sofosbuvir, part of a treatment of hepatitis C that became...
European Pharmaceutical Legislation Needs Exceptions to Data and Market Exclusivity to Protect European Patients...
On 11 May 2018, US President Trump announced his plans to lower drug prices in America. Under the banner "American Patients First" he outlined...
Updated TRIPS Flexibilities Database
In January 2023, a number of cystic-fibrosis patient organisations asked the governments of Brazil, India, South Africa and Ukraine to invoke compulsory licensing and...
Will Europe block the Pandemic Agreement because of one word?
This commentary originally appeared in the Brussels Times, and is available here.
The Pandemic Agreement negotiations began in December of 2021. Sufficiently motivated by the...